

# EARLY EXPERIENCES IN SWITCHING BETWEEN MONOCLONAL ANTIBODIES IN CHRONIC MIGRAINE PREVENTIVE THERAPY

C. Varon-Galcera<sup>1</sup>, A. Gracia-Moya<sup>1</sup>, I. Cardona Pascual<sup>1</sup>, E. Florensa Royo<sup>1</sup>, J. Vidal Otero<sup>1</sup>, G. Vancells Lujan<sup>1</sup>, M.Q. Gorgas Torner<sup>1</sup>

<sup>1</sup>Vall d'Hebron Barcelona Hospital Campus, Pharmacy Department, Barcelona, Spain

Contact email: cvaron@vhebron.net

## Background and Importance

**Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP-mAbs)** are approved for **chronic migraine (CM)** prophylaxis in patients with previous treatment failures. Some patients do not respond to a first CGRP-mAb treatment, but there is no evidence about the effectiveness of **switching** to a second CGRP-mAbs. In Spain, these treatments are only dispensed in **outpatient hospital pharmacies**.

## Aim and Objectives

To describe the **effectiveness** of CGRP-mAbs (erenumab and galcanezumab) **switching** in CM prophylaxis in clinical practice.

## Materials and Methods

- ✓ Observational and retrospective study
- ✓ Patients with CM treated with a CGRP-mAb and switched to another CGRP-mAb

### Clinical variable:

- ✓ Monthly Migraine Days (MMD)
- ✓ Score of Headache Impact Test (HIT-6)

### Study period:

- ✓ Aug 2020 – Sep 2021

### Effectiveness

- ≥50% decrease of MMD compared with baseline
- ≥30% decrease of MMD + ≥5 point's decrease of the HIT-6 compared with baseline

## Results

**N = 20 patients**

### Reasons for treatment switching:

- Non-response to first CGRP-mAb (15 patients)
- Adverse events (5 patients) → severe constipation in patients treated with erenumab

**Median duration of first CGRP-mAb treatment:** 7.8 (5.0 – 9.7) months

	Erenumab → Galcanezumab	Galcanezumab → Erenumab	MMD (%)
<b>Total patients (n)</b>	14	6	-
✓ <b>Effectiveness to CGRP-mAb switch</b>	10	3	-22.6 (12 -40)
✗ <b>Effectiveness to CGRP-mAb switch</b>	2	2	+14.7 (12.5 – 17.8)
⊞ <b>No response to any CGRP-mAb</b>	2	1	-

Any patient presented unacceptable toxicity to the second CGRP-mAb treatment.

## Conclusions and relevance

- ✓ Some patients with chronic migraine and failure to a first monoclonal antibody treatment **may benefit** from switching between antibodies with same mechanism of action.
- ✓ **More studies** are needed to describe which patients respond to CGRP-mAB switching.